BACKGROUND: A rare but recurrent missense mutation (G84E, rs138213197) in the gene homeobox B13 (HOXB13) was recently reported to be associated with hereditary prostate cancer. OBJECTIVE: To explore the prevalence and penetrance of HOXB13 G84E in a general population. DESIGN, SETTING, AND PARTICIPANTS: G84E and 14 additional HOXB13 polymorphisms were genotyped in two population-based, Swedish, case-control samples (Cancer of the Prostate in Sweden [CAPS] and Stockholm-1) comprising 4693 controls and 5003 prostate cancer cases. CAPS collected data on patients and population controls nationally between 2001 and 2003. Stockholm-1 collected data on biopsy-positive patients and biopsy-negative controls in the Stockholm area between 2005 and 2007. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The outcome was pathologically verified prostate cancer. Relative and absolute risks among HOXB13 G84E mutation carriers were explored, as was the combined impact on disease risk of G84E and a polygenic score based on 33 established, common, low-risk variants. RESULTS AND LIMITATIONS: HOXB13 G84E was observed in 1.3% of population controls and was strongly associated with prostate cancer risk (CAPS: odds ratio [OR]: 3.4; 95% confidence interval [CI], 2.2-5.4; Stockholm-1: OR: 3.5; 95% CI, 2.4-5.2). The strongest association was observed for young-onset (OR: 8.6; 95% CI, 5.1-14.0) and hereditary (OR: 6.6; 95% CI, 3.3-12.0) prostate cancer. Haplotype analyses supported that G84E is a founder mutation. G84E carriers have an estimated 33% (95% CI, 23-46) cumulative risk to age 80 yr of prostate cancer, compared to 12% (95% CI, 11-13) among noncarriers. For G84E carriers within the top quartile of a polygenic score of established susceptibility variants, the cumulative risk was estimated at 48% (95% CI, 36-64). CONCLUSIONS: HOXB13 G84E is prevalent in >1% of the Swedish population and is associated with a 3.5-fold increased risk of prostate cancer. One-third of G84E carriers will be diagnosed with prostate cancer, which has implications for surveillance in mutation carriers.
BACKGROUND: A rare but recurrent missense mutation (G84E, rs138213197) in the gene homeobox B13 (HOXB13) was recently reported to be associated with hereditary prostate cancer. OBJECTIVE: To explore the prevalence and penetrance of HOXB13 G84E in a general population. DESIGN, SETTING, AND PARTICIPANTS: G84E and 14 additional HOXB13 polymorphisms were genotyped in two population-based, Swedish, case-control samples (Cancer of the Prostate in Sweden [CAPS] and Stockholm-1) comprising 4693 controls and 5003 prostate cancer cases. CAPS collected data on patients and population controls nationally between 2001 and 2003. Stockholm-1 collected data on biopsy-positive patients and biopsy-negative controls in the Stockholm area between 2005 and 2007. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The outcome was pathologically verified prostate cancer. Relative and absolute risks among HOXB13 G84E mutation carriers were explored, as was the combined impact on disease risk of G84E and a polygenic score based on 33 established, common, low-risk variants. RESULTS AND LIMITATIONS: HOXB13 G84E was observed in 1.3% of population controls and was strongly associated with prostate cancer risk (CAPS: odds ratio [OR]: 3.4; 95% confidence interval [CI], 2.2-5.4; Stockholm-1: OR: 3.5; 95% CI, 2.4-5.2). The strongest association was observed for young-onset (OR: 8.6; 95% CI, 5.1-14.0) and hereditary (OR: 6.6; 95% CI, 3.3-12.0) prostate cancer. Haplotype analyses supported that G84E is a founder mutation. G84E carriers have an estimated 33% (95% CI, 23-46) cumulative risk to age 80 yr of prostate cancer, compared to 12% (95% CI, 11-13) among noncarriers. For G84E carriers within the top quartile of a polygenic score of established susceptibility variants, the cumulative risk was estimated at 48% (95% CI, 36-64). CONCLUSIONS:HOXB13 G84E is prevalent in >1% of the Swedish population and is associated with a 3.5-fold increased risk of prostate cancer. One-third of G84E carriers will be diagnosed with prostate cancer, which has implications for surveillance in mutation carriers.
Authors: Ethan M Lange; Jessica V Ribado; Kimberly A Zuhlke; Anna M Johnson; Gregory R Keele; Jin Li; Yunfei Wang; Qing Duan; Ge Li; Zhengrong Gao; Yun Li; Jianfeng Xu; S Lilly Zheng; Kathleen A Cooney Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-12-15 Impact factor: 4.254
Authors: Jack Cuzick; Mangesh A Thorat; Gerald Andriole; Otis W Brawley; Powel H Brown; Zoran Culig; Rosalind A Eeles; Leslie G Ford; Freddie C Hamdy; Lars Holmberg; Dragan Ilic; Timothy J Key; Carlo La Vecchia; Hans Lilja; Michael Marberger; Frank L Meyskens; Lori M Minasian; Chris Parker; Howard L Parnes; Sven Perner; Harry Rittenhouse; Jack Schalken; Hans-Peter Schmid; Bernd J Schmitz-Dräger; Fritz H Schröder; Arnulf Stenzl; Bertrand Tombal; Timothy J Wilt; Alicja Wolk Journal: Lancet Oncol Date: 2014-10 Impact factor: 41.316
Authors: Daniel C Koboldt; Krishna L Kanchi; Bin Gui; David E Larson; Robert S Fulton; William B Isaacs; Aldi Kraja; Ingrid B Borecki; Li Jia; Richard K Wilson; Elaine R Mardis; Adam S Kibel Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-08-02 Impact factor: 4.254
Authors: Chee L Goh; Edward J Saunders; Daniel A Leongamornlert; Malgorzata Tymrakiewicz; Karen Thomas; Elizabeth D Selvadurai; Ruth Woode-Amissah; Tokhir Dadaev; Nadiya Mahmud; Elena Castro; David Olmos; Michelle Guy; Koveela Govindasami; Lynne T O'Brien; Amanda L Hall; Rosemary A Wilkinson; Emma J Sawyer; Ali Amin Al Olama; Douglas F Easton; Zsofia Kote-Jarai; Chris C Parker; Rosalind A Eeles Journal: BJU Int Date: 2013-01-15 Impact factor: 5.588
Authors: Sofia Maia; Marta Cardoso; Paula Paulo; Manuela Pinheiro; Pedro Pinto; Catarina Santos; Carla Pinto; Ana Peixoto; Rui Henrique; Manuel R Teixeira Journal: Fam Cancer Date: 2016-01 Impact factor: 2.375
Authors: Shaheen Alanee; Sohela Shah; Joseph Vijai; Kasmintan Schrader; Robert Hamilton; Rohini Rau-Murthy; Kara Sarrel; Christopher Manschreck; James Eastham; Kenneth Offit Journal: Fam Cancer Date: 2013-12 Impact factor: 2.375